These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28280971)

  • 61. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
    Tran B; Carvajal RD; Marabelle A; Patel SP; LoRusso PM; Rasmussen E; Juan G; Upreti VV; Beers C; Ngarmchamnanrith G; Schöffski P
    J Immunother Cancer; 2018 Sep; 6(1):93. PubMed ID: 30253804
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
    Liu D; Zhou J; Wang Y; Li M; Jiang H; Liu Y; Yin X; Ge M; Xiang X; Ying J; Huang J; Zhang YQ; Cheng Y; Huang Z; Yuan X; Han W; Yan D; Wang X; Liu P; Wang L; Zhang X; Luo S; Liu T; Shen L
    BMC Med; 2022 Oct; 20(1):408. PubMed ID: 36280870
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
    Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
    Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
    Mullamitha SA; Ton NC; Parker GJ; Jackson A; Julyan PJ; Roberts C; Buonaccorsi GA; Watson Y; Davies K; Cheung S; Hope L; Valle JW; Radford JA; Lawrance J; Saunders MP; Munteanu MC; Nakada MT; Nemeth JA; Davis HM; Jiao Q; Prabhakar U; Lang Z; Corringham RE; Beckman RA; Jayson GC
    Clin Cancer Res; 2007 Apr; 13(7):2128-35. PubMed ID: 17404096
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
    Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
    Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
    Baselga J; Pfister D; Cooper MR; Cohen R; Burtness B; Bos M; D'Andrea G; Seidman A; Norton L; Gunnett K; Falcey J; Anderson V; Waksal H; Mendelsohn J
    J Clin Oncol; 2000 Feb; 18(4):904-14. PubMed ID: 10673534
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
    J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
    Attard G; Kitzen J; Blagden SP; Fong PC; Pronk LC; Zhi J; Zugmaier G; Verweij J; de Bono JS; de Jonge M
    Br J Cancer; 2007 Nov; 97(10):1338-43. PubMed ID: 18000498
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
    Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
    Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
    Annunziata CM; Kohn EC; LoRusso P; Houston ND; Coleman RL; Buzoianu M; Robbie G; Lechleider R
    Invest New Drugs; 2013 Feb; 31(1):77-84. PubMed ID: 22370972
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
    Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
    Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
    Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
    Smith DC; Chugh R; Patnaik A; Papadopoulos KP; Wang M; Kapoun AM; Xu L; Dupont J; Stagg RJ; Tolcher A
    Invest New Drugs; 2019 Aug; 37(4):722-730. PubMed ID: 30591982
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
    Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
    Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
    LoRusso P; Jänne PA; Oliveira M; Rizvi N; Malburg L; Keedy V; Yee L; Copigneaux C; Hettmann T; Wu CY; Ang A; Halim AB; Beckman RA; Beaupre D; Berlin J
    Clin Cancer Res; 2013 Jun; 19(11):3078-87. PubMed ID: 23591447
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
    Machiels JP; Salazar R; Rottey S; Duran I; Dirix L; Geboes K; Wilkinson-Blanc C; Pover G; Alvis S; Champion B; Fisher K; McElwaine-Johnn H; Beadle J; Calvo E
    J Immunother Cancer; 2019 Jan; 7(1):20. PubMed ID: 30691536
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
    Weiner LM; Belldegrun AS; Crawford J; Tolcher AW; Lockbaum P; Arends RH; Navale L; Amado RG; Schwab G; Figlin RA
    Clin Cancer Res; 2008 Jan; 14(2):502-8. PubMed ID: 18223225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.